BR0009592A - Composição anti-diabética, e, método para tratamento de diabetes mellitus - Google Patents

Composição anti-diabética, e, método para tratamento de diabetes mellitus

Info

Publication number
BR0009592A
BR0009592A BR0009592-3A BR0009592A BR0009592A BR 0009592 A BR0009592 A BR 0009592A BR 0009592 A BR0009592 A BR 0009592A BR 0009592 A BR0009592 A BR 0009592A
Authority
BR
Brazil
Prior art keywords
diabetes mellitus
treating diabetes
diabetic composition
insulin
treatment
Prior art date
Application number
BR0009592-3A
Other languages
English (en)
Inventor
Randy H Ziegler
Original Assignee
Randy H Ziegler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Randy H Ziegler filed Critical Randy H Ziegler
Publication of BR0009592A publication Critical patent/BR0009592A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

"COMPOSIçãO ANTI-DIABéTICA, E, MéTODO PARA TRATAMENTO DE DIABETES MELLITUS". Produtos extraídos de Brickellia californica e flavonóides isolados, incluindo apigenina, luteolina, quercetina e diidroxicaenferol, purificados oriundos Brickellia californica, são utilizáveis para o tratamento de diabetes. Os produtos extraídos e os flavonóides purificados podem ser usados alternativamente no tratamento de diabetes dependente da insulina e não dependente da insulina, porque estes materiais resultam em significativo abaixamento do açúcar do sangue.
BR0009592-3A 1999-04-05 2000-04-04 Composição anti-diabética, e, método para tratamento de diabetes mellitus BR0009592A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12782499P 1999-04-05 1999-04-05
PCT/US2000/008957 WO2000059522A1 (en) 1999-04-05 2000-04-04 Compositions and methods for treatment of diabetes

Publications (1)

Publication Number Publication Date
BR0009592A true BR0009592A (pt) 2002-01-08

Family

ID=22432145

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009592-3A BR0009592A (pt) 1999-04-05 2000-04-04 Composição anti-diabética, e, método para tratamento de diabetes mellitus

Country Status (7)

Country Link
EP (1) EP1169047A1 (pt)
JP (1) JP2002541116A (pt)
AU (1) AU780233B2 (pt)
BR (1) BR0009592A (pt)
CA (1) CA2368215A1 (pt)
MX (1) MXPA01010037A (pt)
WO (1) WO2000059522A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068704A1 (en) * 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
DE60141253D1 (de) * 2000-12-21 2010-03-25 The Quigley Corp Methode und zusammensetzung zur behandlung diabetischer neuropathie
JP2005504796A (ja) * 2001-09-06 2005-02-17 シノークス インコーポレイテッド ３−デオキシフラボノイドによるｔ−リンパ球活性化の阻害および関連療法
EP1501520A1 (en) 2002-05-06 2005-02-02 Diakron Pharmaceuticals, Inc. Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
EP1708689A2 (en) * 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
JP2008007452A (ja) * 2006-06-28 2008-01-17 Ajinomoto Co Inc 膵β細胞保護剤
US8287677B2 (en) 2008-01-31 2012-10-16 Kimberly-Clark Worldwide, Inc. Printable elastic composite
JP5594719B2 (ja) * 2010-01-06 2014-09-24 国立大学法人神戸大学 筋肉の糖取り込み促進剤

Also Published As

Publication number Publication date
EP1169047A1 (en) 2002-01-09
CA2368215A1 (en) 2000-10-12
AU780233B2 (en) 2005-03-10
WO2000059522A1 (en) 2000-10-12
MXPA01010037A (es) 2003-07-14
JP2002541116A (ja) 2002-12-03
AU4196400A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
DE59508891D1 (de) Hautpflegemittel
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
BR0009592A (pt) Composição anti-diabética, e, método para tratamento de diabetes mellitus
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
ATE29729T1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BR0114310A (pt) Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE69401204T2 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
BR0014384A (pt) Compostos para o tratamento da isquémia
WO2001006984A3 (en) Small molecules useful in the treatment of inflammatory disease
DK15589A (da) Kemiske forbindelser
IL113782A0 (en) Compositions containing flubendazole their preparation and their use
ES2177642T3 (es) Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.
FI971951A (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
NO934836D0 (no) Fremgangsmaate for fremstilling og anvendelse som medikament eller diagnostikum av 2,4-substituerte 5-(N-substituerte-sulfamoyl)-benzoylgu anidiner, og medikamenter som inneholder disse
SE9904581D0 (sv) A novel helicobacter pylori-binding substance and use thereof
DE3767849D1 (de) Arzneimittel zur vorbeugung und behandlung der alkoholischen toxicomanie und verfahren zu ihrer herstellung.
DE3481057D1 (de) 2-sulfamoylbenzo(b)thiophen-derivate, ihre herstellung und pharmazeutische zubereitung zur behandlung von erhoehtem augeninnendruck.
IE894050L (en) Compound with gastric acid inhibitory effect and process for¹its preparation
FR2687933B1 (fr) Produits antimottants, compositions contenant ces produits et traitements mettant ces produits en óoeuvre.
NO995685D0 (no) Nye glycosylerte ginkgolidderivater, anvendelse derav som medikamenter og farmasöytiske blandinger
WO2002070507A3 (en) Glycorticoid receptor antagonists for treatment of diabetes
ATE95167T1 (de) Aromatische carbonsaeureamide, ihre herstellung und verwendung fuer heilmittel.
NO965468D0 (no) Farmasöytisk preparat for forhindring og/eller behandling av virale infeksjoner og eventuelle inflammasjoner, så vel som en behandlingsmetode derfor

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 9A E 10A ANUIDAD(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.

B15K Others concerning applications: alteration of classification

Ipc: G01N 33/68 (2006.01), A61K 36/28 (2006.01), G01N 3